Abstract: A corner protector is provided with a body with a recess formed in the body. The recess defines a first surface to receive and contact a pane surface of a pane in the recess. The recess defines a second surface angled relative to the first surface and intersecting the first surface to receive and contact a first edge surface of the pane. The recess defines a third surface angled relative to the first surface and the second surface and intersecting the first surface to receive and contact a second edge surface of the pane. The body defines an aperture formed in the first surface and oriented at a convergence of the first surface, the second surface, and the third surface such that the second surface and the third surface do not intersect. The aperture is formed to a blind depth in the body.

Abstract: A method for controlling a driving mode, includes: detecting an action of an operating member; in response to the action of the operating member, generating a driving control instruction; and controlling a driving object to execute or exit a target driving mode according to the driving control instruction, wherein the target driving mode comprises a general driving mode and an intelligent driving mode.

Abstract: The present disclosure provides compounds represented by Formula I, or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula I are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.

Abstract: In an approach for building file server arrays with stable and unstable nodes for enhanced pipeline transmission, a processor builds an array from a plurality of stable nodes, wherein each stable node of the plurality of stable nodes is linked to two other stable nodes of the plurality of stable nodes forming a line. A processor divides a plurality of unstable nodes into one or more groups of unstable nodes. A processor links each group of unstable nodes to two neighboring stable nodes within the array. A processor sends data through the array and the one or more groups of unstable nodes in two opposite directions. A processor monitors a node status for each node of the plurality of stable nodes and the plurality of unstable nodes.

Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: Disclosed is a method for synthesizing N-(phenylsulfonyl)benzamide compound and intermediate thereof. The method comprises a method for synthesizing a compound 1, comprising conducting a Buchwald-Hartwig coupling reaction as shown below with compound A and compound B in a solvent and in the presence of a base and a palladium catalyst to obtain the compound 1; wherein R is C1-C8 alkyl. The present disclosure synthesizes three intermediate compounds required by the target compound and their preparation methods for the first time. Using the method disclosed in the present disclosure to synthesize the target compound 3 has the advantages of high yield, good purity, easy-to-obtain reaction raw materials, suitable for industrial production.

Abstract: In an approach for building file server arrays with stable and unstable nodes for enhanced pipeline transmission, a processor builds an array from a plurality of stable nodes, wherein each stable node of the plurality of stable nodes is linked to two other stable nodes of the plurality of stable nodes forming a line. A processor divides a plurality of unstable nodes into one or more groups of unstable nodes. A processor links each group of unstable nodes to two neighboring stable nodes within the array. A processor sends data through the array and the one or more groups of unstable nodes in two opposite directions. A processor monitors a node status for each node of the plurality of stable nodes and the plurality of unstable nodes.

Abstract: A transfer device including at least one first transfer component and at least one second transfer component are provided. The first transfer component includes a first carrier pad contacting the transferred object, and the second transfer component includes a second carrier pad contacting the transferred object, and material of the first carder pad has stronger capability to capture electrons than that of the second carrier pad and material of the second carrier pad has stronger capability to lose electrons than that of the first carder pad.

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2a, R2b, R2c, R2d, R3, R4a, R4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.

Abstract: The present disclosure provides compounds represented by Formula I, or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula I are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.

Abstract: A mask plate and a mask sheet are provided. The mask plate includes a first mask sheet and a second mask sheet, the first mask sheet includes a first mask area located in a middle region of the first mask sheet and first peripheral areas located on both sides of the first mask area in a first direction, a thickness of the first mask area is less than a thickness of the first peripheral areas to form a first concave portion; the second mask sheet includes a second mask area located in a middle region of the second mask sheet and second peripheral areas located on both sides of the second mask area in a second direction, a thickness of the second mask area is less than a thickness of the second peripheral areas to form a second concave portion.

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: A transfer device including at least one first transfer component and at least one second transfer component are provided. The first transfer component includes a first carrier pad contacting the transferred object, and the second transfer component includes a second carrier pad contacting the transferred object, and material of the first carder pad has stronger capability to capture electrons than that of the second carrier pad and material of the second carrier pad has stronger capability to lose electrons than that of the first carder pad.

Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.